Share-Based Compensation (Tables)

9 Months Ended

Mar. 31, 2018

Share-Based Compensation

Schedule of weighted average assumptions used to estimate fair values of the stock options granted and the estimated annual forfeiture rates used to recognize the associated compensation expense and the weighted average fair value of the options granted

	Nine Months Ended
	March 31, 2018			March 31, 2017
Risk-free interest rate	2.12		%	1.1		%
Expected volatility	57.6		%	55.6		%
Expected dividend yield	—		%	—		%
Forfeiture rate	6.5		%	6.5		%
Expected term (in years)	5.4 years			5.2 years
Weighted average fair value	$	11.25		$	15.33

Summary of stock option award activity

(In thousands, except for weighted average price and life data)	Awards		Weighted- Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Life (yrs.)
Outstanding at June 30, 2017	1,475		$	18.02	$	12,212	5.7
Granted	50		$	21.43
Exercised	(404	)	$	7.13	$	3,897
Forfeited, expired or repurchased	(20	)	$	32.31
Outstanding at March 31, 2018	1,101		$	21.93	$	4,205	5.6
Vested and expected to vest at March 31, 2018	1,096		$	21.92	$	4,205	5.6
Exercisable at March 31, 2018	1,044		$	21.60	$	4,205	5.4

Summary of nonvested restricted stock awards

(In thousands, except for weighted average price and life data)	Awards		Weighted Average Grant - date Fair Value		Aggregate Intrinsic Value
Non-vested at June 30, 2017	334		$	30.71
Granted	588		$	18.24
Vested	(177	)	$	31.30	$	3,901
Forfeited	(57	)	$	21.70
Non-vested at March 31, 2018	688		$	20.63

Schedule of nonvested performance-based shares

(In thousands, except for weighted average price and life data)	Awards		Weighted Average Grant - date Fair Value		Aggregate Intrinsic Value
Non-vested at June 30, 2017	—		$	—
Granted	47		$	25.58
Vested	(21	)	$	25.58	$	500
Forfeited	—		$	—
Non-vested at March 31, 2018	26		$	25.58

Schedule of allocation of share-based compensation costs recognized in the Consolidated Statements of Operations by financial statement line item

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
(In thousands)	2018		2017		2018		2017
Selling, general and administrative expenses	$	1,638	$	1,345	$	5,350	$	4,568
Research and development expenses	149		175		477		500
Cost of sales	478		269		1,191		894
Total	$	2,265	$	1,789	$	7,018	$	5,962
Tax benefit at statutory rate	$	668	$	653	$	2,070	$	2,176